- Home
- BEAM vs NG Comparison
BEAM vs NG Comparison
Compare BEAM & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- NG
- Stock Information
- Founded
- BEAM 2017
- NG 1984
- Country
- BEAM United States
- NG Canada
- Employees
- BEAM N/A
- NG N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- NG Precious Metals
- Sector
- BEAM Health Care
- NG Basic Materials
- Exchange
- BEAM Nasdaq
- NG Nasdaq
- Market Cap
- BEAM 1.7B
- NG 1.5B
- IPO Year
- BEAM 2020
- NG N/A
- Fundamental
- Price
- BEAM $25.79
- NG $10.41
- Analyst Decision
- BEAM Strong Buy
- NG Strong Buy
- Analyst Count
- BEAM 11
- NG 3
- Target Price
- BEAM $49.40
- NG $10.17
- AVG Volume (30 Days)
- BEAM 2.3M
- NG 5.4M
- Earning Date
- BEAM 11-04-2025
- NG 10-01-2025
- Dividend Yield
- BEAM N/A
- NG N/A
- EPS Growth
- BEAM N/A
- NG N/A
- EPS
- BEAM N/A
- NG N/A
- Revenue
- BEAM $60,272,000.00
- NG N/A
- Revenue This Year
- BEAM N/A
- NG N/A
- Revenue Next Year
- BEAM $18.95
- NG N/A
- P/E Ratio
- BEAM N/A
- NG N/A
- Revenue Growth
- BEAM N/A
- NG N/A
- 52 Week Low
- BEAM $13.53
- NG $2.26
- 52 Week High
- BEAM $35.25
- NG $10.90
- Technical
- Relative Strength Index (RSI)
- BEAM 57.00
- NG 74.58
- Support Level
- BEAM $23.53
- NG $9.54
- Resistance Level
- BEAM $28.75
- NG $10.90
- Average True Range (ATR)
- BEAM 1.76
- NG 0.47
- MACD
- BEAM -0.13
- NG 0.12
- Stochastic Oscillator
- BEAM 50.50
- NG 85.42
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.